Investment story

Cereno Scientific is a clinical stage biotech company striving to disrupt cardiovascular treatments worldwide by unlocking the potential of epigenetic modulation in common and rare diseases. Cardiovascular disease is the number 1 cause of death globally, killing nearly twice as many people as cancer. An estimated 17.8 million people died from CVD in 2017 – a number that is growing every year. Of these deaths, 85% are due to thrombotic indications such as heart attack and stroke.

Our pipeline comprises:

  • Drug candidate CS1 in Phase II study being developed for the treatment of rare disease pulmonary arterial hypertension (PAH). 
  • Two preclinical programs, CS585 and CS014, evaluated for the treatment of cardiovascular diseases. 

 

Cereno Scientific's B share has been listed on Spotlight Stock Market since June 2016 with the ticker CRNO B.

Share capital development

Overview

Shares of series A warrant ten (10) votes per one (1) share and shares of series B warrant one (1) vote per one (1) share. The shares ratio value amounts to 0,1 SEK. All shares entitle the shareholder to equal rights to share the company’s assets and earnings.

Updated: December 2020

YearEventRatio value (SEK)Difference in sharesChange (SEK) Total number of sharesTotal share capital (SEK)
2012Formation150 00050 00050 00050 000
2012Rights issue110 60510 60560 60560 605
2016Directed issue11 2001 20061 80561 805
2016Stock dividend issue10556 24561 805618 050
2016Share split 100:10.16 118 6956 180 500618 050
2016Subdivision A-/B- shares0.106 180 500
2016Directed issue0.10 1 420 000 1 420 0007 600 500760 050
2016Directed issue0.10450 00045 0008 050 500805 050
2016IPO0.102 940 000294 00010 990 5001 099 050
2018Conversion0.10188 67918 867.9011 179 1791 117 917.90
2018Conversion0.10444 44444 444.4011 623 6231 162 362.30
2018Conversion0.10540 54054 05412 164 1631 216 416.30
2018Conversion0.10483 870483 870012 648 0331 264 803.30
2018Conversion0.10419 35441 935.4013 067 3871 306 738.70
2018Conversion0.10384 61438 461.4013 452 0011 345 200.10
2018Conversion0.10269 23026 92313 721 2311 372 123.10
2018Conversion0.10307 69230 769.2014 028 9231 402 892.30
2018Conversion0.10333 33333 333.3014 362 2561 436 225.60
2018Conversion0.10285 71428 571.4014 647 9701 464 797.00
2019Conversion0.10533 33353 333.3015 181 3031 518 130.30
2019Conversion0.10666 66666 666.6015 847 9691 584 796.90
2019Conversion0.103 333 333333 333.3019 181 3021 918 130.20
2019Rights issue0.1019 181 3021 918 130.2038 362 6043 836 260.40
2019Overallotment issue0.101 724 137172 413.7040 086 7414 008 674.10
2019Remuneration issue0.10132 57113 257.1040 219 3124 021 931.20
2020Rights issue0.131 600 0003 160 00071 819 3127 181 931.20

Dividend policy

Dividend policy

Cereno will continue to focus on developing and expanding the company’s pipeline. Cereno scientific have not yet paid any dividend and the companys board does not intend to propose any dividend within the next two years. Any profits will instead be reinvested in the Company’s product and business developement to finance the company’s long-term strategy. Any future dividends and the size thereof is determined based on the company’s long-term growth, earnings trend, and capital requirements, taking into account the current objectives and strategies adopted.

Largest shareholders

Share issues

Our share issues

Access information related to the company’s current and/or previous share issues. Information is in Swedish only.

Nyemission 2019

Read more

IPO 2016

Read more

Financial calendar

9 June 2021

AGM 2021

19 May 2021

Interim report Q1, 2021

5 May 2021

Annual report 2020

25 February 2021

Year-end report (Q4), 2020

19 November 2020

Interim report Q3, 2020

29 September 2020

Extraordinary General Meeting

10 June 2020

Annual General Meeting 2020

28 August 2020

Half-year report (Q2), 2020

Subscribe to our news

Get immediate updates, subscribe to our news.